Literature DB >> 2565743

Profound bradycardia after addition of diltiazem to a beta blocker.

A B Hassell1, J E Creamer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2565743      PMCID： PMC1835854          DOI： 10.1136/bmj.298.6674.675

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Calcium-entry blockage: basic concepts and clinical implications.

Authors: 
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

2.  Effort angina with adequate beta-receptor blockade: comparison with diltiazem alone and in combination.

Authors:  D P Humen; P O'Brien; P Purves; D Johnson; W J Kostuk
Journal:  J Am Coll Cardiol       Date:  1986-02       Impact factor: 24.094

3.  The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study.

Authors:  J Hung; I H Lamb; S J Connolly; K R Jutzy; M L Goris; J S Schroeder
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

4.  Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris.

Authors:  M J O'Hara; N S Khurmi; M J Bowles; E B Raftery
Journal:  Clin Cardiol       Date:  1987-02       Impact factor: 2.882

Review 5.  Treatment of stable angina pectoris with calcium antagonists alone or combined with beta-blocking agents: a review of the literature.

Authors:  L G Bélanger; M Charbonneau; J P Lavallée; J Lenis; A C Ouellet
Journal:  Can J Cardiol       Date:  1986 Jul-Aug       Impact factor: 5.223
  5 in total
  3 in total

1.  Are beta blockers and nifedipine safe?

Authors:  I H Stockley
Journal:  BMJ       Date:  1989-06-10

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Adverse effects using combined rate-slowing antihypertensive agents.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.